Aptamer Group PLC said on Tuesday that it has extended its contract with Unilever PLC for the development of novel Optimer binders for use in deodorant products.
The York, England-based biotechnology firm will partner with Unilever, the London-based consumer goods firm, to continue its work in testing Optimer binders as active ingredients in deodorants.
Aptamer said the use of active ingredients like Optimer binders in deodorant products is ‘highly novel’ and ‘holds the potential for enhanced efficacy for customer products’. Optimer binders target the C-S Lyase bacterial enzyme, which is critical in the generation of auxiliary odour.
The contract follows successful laboratory tests of the Optimer binders, allowing the partnership to progress to planned in-vivo studies before the end of 2024.
Aptamer Chief Executive Officer Arron Tolley said: ‘The continued advancement of our Optimer binders in collaboration with Unilever is a significant milestone for Aptamer Group. With efficacy testing on the horizon, we are optimistic about bringing these binders to market in the coming years and look forward to discussing commercial opportunities with Unilever upon successful trial outcomes.’
Aptamer Group share prices were up 8.7% to 0.25 pence each in London on Tuesday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
